Home Medicine Tumor microenvironment in treatment of glioma
Article Open Access

Tumor microenvironment in treatment of glioma

  • Guijie Li , Zhigang Qin , Zhuo Chen , Lijuan Xie , Ren Wang and Hang Zhao EMAIL logo
Published/Copyright: August 12, 2017

Abstract

Glioma is one of the most malignant and fatal tumors in adults. Researchers and physicians endeavor to improve clinical efficacy towards it but made little achievement. In recent years, people have made advances in understanding characteristics and functions of tumor microenvironment and its role in different processes of tumor. In this paper, we describe the effects of tumor microenvironment on glioma proliferation, invasion and treatments. By explaining underlying mechanisms and enumerating new therapy strategies employing tumor microenvironment, we aim to provide novel ideas to improve clinical outcomes of glioma.

1 Introduction

The occurrence, progress and invasion of tumor are closely related with the microenvironment surrounding the tumor, which is a network including various cell types, stroma, blood vessels, secreted factors, surrounding matrix and also inner environment of tumor cells. Tumor cells can change and maintain their ambience through autocrine and paracrine to promote their own proliferation and development. There exist mutual dependency, promotion, antagonism and fight between tumor and the environment. With recent achievements in oncocytology and molecular biology, we have got a deeper understanding on relationship of tumor and its microenvironment, which means a lot in study, diagnosis, treatment and prognosis of tumors. In immunotherapies for tumors, positive responds are usually depending on the interaction of tumor cells and immunoregulation in tumor microenvironment. Tumor microenvironment plays a crucial role in suppression or enhancement of immune response. A good understanding of tumor microenvironment and its mutual effects with tumor is important to more than reveal the mechanisms but also provide new strategies to improve efficacy of immunotherapies.

Glioma is one of the most common and aggressive primary tumors in adults. Despite improved insight into the underlying molecular mechanisms, it is still hard to be treated and the prognosis of patients remains poor due to fast progress and scarcity of effective treatment strategies. The highly heterogeneous tumor microenvironment plays a substantial role in tumor malignancy and treatment responses. It is also related with resistance of glioma cells to chemotherapy [1]. In this review, we summarized influences of tumor microenvironment on glioma cells behaviors, clinical efficacy and prognosis of glioma, revealed possible underlying mechanisms and shared some therapy strategies that utilizing characteristics of microenvironment to improve clinical outcomes [2-5].

2 Tumor microenvironment and glioma and related mechanisms

As the most abundant glial cells in glioma microenvironment, astrocytes significantly contribute to glioma pathogenesis. Activated astrocytes surround and infiltrate glioma cells and protect them from cytotoxic effects caused by various chemotherapeutic agents. As one of the major stromal cells in the brain, astrocytes are closely related to the malignant phenotype of gliomas, and they play important roles in chemo-resistance of gliomas. Recent studies showed that through direct contact with glioma cells and infiltrating around the tumor, astrocytes demonstrated protective effects for glioma against chemotherapeutic drugs, which might reveal the mechanism underlying the unsatisfactory clinical outcomes of chemotherapy [6, 7]. The gap junctional communication (GJC) between glioma cells and astrocytes has presented protective effect via expression levels regulation of various critical survival genes by astrocytes. That result indicated that the microenvironment may affect the behavior of tumor cells and might be related with resistance in glioma cells [8]. Astrocytes could increase the secretion of IL-6 and induce the expression of membrane type 1 matrix metalloproteinase (MMP14), and thus enhance the migration and invasion of gliomas, which is a proof of influence of microenvironment on tumor processes [9]. A syngeneic model of glioma resection and recurrence in mice was developed and influences of surgical resection on glioma biology and the local microenvironment were examined. Results demonstrated that resection-induced injury led to alterations in reactive astrocytes in the peritumoral microenvironment and astrocyte injury induced changes in transcriptome and secretome as well as promotion of tumor proliferation and migration. That indicates a necessity of further knowledge of the postsurgical tumor microenvironment for targeted anticancer agents development [10].

Myeloid-derived suppressor cells (MDSCs) constitute >40% of the infiltrating immune cells and can accumulate to induce immunosuppression in glioma. MDSCs can also secret many kinds of cytokines that are involved in antigen-specific T cell suppression. Researchers demonstrated that depletion or blockade of MDSCs augment the efficacy of immunotherapy, which presented promise for increasing the efficacy of immunotherapies for glioma [11]. Within the glioma microenvironment, macrophages and microglia could produce CCL2, which is critical for recruiting MDSCs and regulatory T cells (Treg). In clinical specimens of glioma, enhanced expression of CCL2 is related with reduced overall survival. This is another proof of how tumor microenvironment induces immunosuppression and drive glioma progression [12].

Heparanase (HPSE), which cleaves Heparan sulfate proteoglycans (HSPG), breaks down modified sugar chains on cell surfaces as well as in the extracellular space. Its level is positively correlated with tumor development in the brain. Tumor microenvironment, reactive astrocytes, microglia/monocytes and tumor angiogenesis are also influenced by HPSE. HPSE is highly expressed in glioma and inhibition of HPSE reduces glioma cell numbers. Furthermore, high levels of HPSE appeared to be related with shorter survival in patients with highgrade glioma. These data provide proof for anti-HPSE treatment of glioma [13].

B7-H4 (B7x/B7S1) is a B7 family member whose expression in tumors was associated with prognosis malignant grades of glioma. Silencing of B7-H4 expression in glioma and microenvironment supporting cells lead to increased microenvironment T-cell function and tumor inhibition, which made it an important immunosuppressive event holding back effective T-cell immune responses and a potential therapy target [14].

Tumor microenvironment can also drive resistance to inhibition of colony-stimulating factor-1 receptor (CSF-1R), which targets macrophages accumulate in glioma progression. Mechanisms of this effect conclude IGF-1 induced phosphatidylinositol 3-kinase (PI3K) pathway activity [15].

EGFR amplification and mutation, especially EGFRvIII are the mostly found signatures in glioma. Researchers demonstrated that hypoxia tumor microenvironment and ECM vitronectin could enhance tumor cell invasion and EGFRvIII activity through EGFRvIII and integrin β3 complex, emphasizing key roles of tumor microenvironment in tumor progression and metastasis [16].

Extracellular matrix tenascin-C (TNC) consist the brain tumor microenvironment. Studies show that decreased TNC leads to tumor invasion reduction and tumor proliferation increase, which means that tumor microenvironment, modulates stromal cells behaviors and influences tumor behavior as well [17].

Ca2+-activated K+ channel (KCa3.1) is expressed in both glioma and infiltrating microglia/macrophages (M/MΦ) and is involved in glioma progress promotion under mechanisms including FAK and PI3K/AKT. Inhibition of KCa3.1 would lead to a switch of M/MΦ cells toward a pro-inflammatory, antitumor phenotype and contribute to glioma development reduction, suggesting a possible role for KCa3.1 as a therapeutic target in glioma [18].

As an important gap junction protein in astrocytes, connexin43 (Cx43) is over-expressed in glioma-associated astrocytes at the peri-tumoral region. Cx43 increases malignancy in tumor cells through mediating intercellular communication. And expression of Cx43 is related with glioma cells dissemination from the tumor core by manipulating the microenvironment [19].

A study has proved that tumor microenvironment can facilitate malignant transformation of bone marrow stromal cells (BMSCs) into glioma cancer stem cells (CSCs) [20].

Exosomes are one type of extracellular vesicles (EVs), which mediate intercellular communication for normal and tumor cells as well. Exosomes secreted by tumor cells take parts in different tumor processes and modify tumor microenvironment for progression. The roles exosomes play in cross-talk within tumor microenvironment and intercellular communication make them tumor biomarkers and a potential therapeutic target/delivery system [21].

3 New therapy strategies

3.1 Drug delivery system

Advances have been achieved in active targeting drug delivery system (DDS) in glioma diagnosis and therapy. Lack of sufficient targets on glioma cells and limited penetration capability of DDS significantly compromise the treatment efficacy. So it is important to explore effective receptor targets. Researchers constructed dual-decorated nanoparticulate DDS loaded with paclitaxel (PTX). By taking advantages of the tumor microenvironment dual-targeting and angiogenic blood vessels effect, this DDS extensively accumulated at glioma site and resulted in improved anti-glioma efficacy with enhanced penetration capability in vivo, which made it a promising drug delivery method in glioma treatment [22].

In another research, nanoparticles (NPs) were related with a substrate of large amino acid transporter 1 (LAT1) that is overexpressed in both blood-brain-barrier and glioma cells. And as levels of adenosine-5’-triphosphate (ATP) and glutathione (GSH) are remarkably diverse between extracellular and intracellular milieu, the doxorubicin (DOX)-conjungated NPs were designed to be targeting both ATP&GSH. Results showed that both enhanced NP accumulation and rapid DOX release in glioma were demonstrated, with more efficient therapeutic effects and no systemic toxicity observed. This study proved the feasibility of GSH & ATP dual-responsive utilizing microenvironment strategy to improve efficacy of chemotherapy for glioma [23].

Based on the cognition that the pH environment in gliomas is acidic, people constructed pH-sensitive liposomes with DOX encapsulated in them. Responding to the acidic pH in glioma, a specific targeting drug release was observed. Anti-tumor activity of the liposomes was also demonstrated in the in vivo experiment, which made those particles one of the drug delivery systems that are suitable for targeting anti-tumor therapy [24].

In a study, a delivery system based on gold nanoparticle was developed. The nanoparticles loading DOX were coated with PEG. Results showed that the release of DOX was pH-dependent and cellular uptake as well as glioma distribution were both at a higher intensity. Longer median survival time was also acquired in glioma-bearing mice, making these nanoparticles a feasible drug delivery system [25].

PEG-PLA nanoparticles were designed to target fibronectins (FNs), which is a prevailing component in the abundant extracellular matrix (ECM). ECM is abundant in the glioma microenvironment and play a critical role in different tumor progresses. This FN-targeting drug delivery system loaded with paclitaxel demonstrated favored penetration into glioma spheroids and significant proliferation inhibitive effects as well as prolonged survival time, proving that ECM could be a potential target for drug delivery in clinical applications [26].

3.2 Viroimmunotherapy

Vesicular stomatitis virus (VSV) expressing a complementary cDNA library is applicated in tumors treatments by vaccinating against tumor associated antigens (TAAs). This systemic viroimmunotherapy consisting of histological type-specific antigens and location-specific antigens against gliomas achieved satisfying immune responses, which could be enhanced by immune checkpoint inhibitors. That indicates that VSV-TAA therapy, combined with checkpoint inhibition, has got clinical values, as well as the importance of the tumor microenvironment in immunotherapy [27].

In an intratumoral virotherapy research, an oncolytic adenovirus was administrated intratumorally. Decreased tumor-infiltrating Tregs and increased IFNγ-producing CD8+ T cells was observed, even in highly immunosuppressive tumor microenvironment in late stage diseases. Additionally, this treatment could enhance systemically transferred tumor-antigen-specific T cell therapy and reprogram immunosuppressive Tregs to a stimulatory state [28].

In one study, adoptive immunotherapy with transferred antigen-specific T cells is adopted. Researchers combined systemic injection of bacterial lipoprotein (BLP), a TLR1/2 agonist, with that therapy. BLP could maintain T cell persistence, modify the tumor microenvironment and even induce systemic anti-tumor immunity and thus improve the adoptive T cell therapy, which might offer a strategy to overcome the obstacles for immunotherapy for glioma [29].

3.3 Antiangiogenic therapy

Antiangiogenic therapy added to immunotherapeutic approaches towards glioma has achieved clinical benefits, among which the endogenous microenvironment or vaccine-induced inflammatory responses is importantly subsidiary to its effectiveness. An inhibitor of vascular endothelial growth factor, aflibercept, was applied in combination with an antitumor vaccine. Delayed tumor progression and survival extension were observed, which confirmed the efficacy of combining antiangiogenic and immunotherapy approaches as well as the value of delineating tumor microenvironment [30].

Sunitinib, a small molecule with known anti-angiogenic effect, was found to induce glioma cell death by targeting VEGFR2 while protecting neurons and astrocytes. Sunitinib could normalize the tumor-derived aberrant vasculature and reduce tumor vessel pathologies multitargeted receptor tyrosine kinase inhibitor, on constituents of the tumor microenvironment such as gliomas, astrocytes, endothelial cells, and neurons. Sunitinib has a. We found that sunitinib normalizes the aberrant tumor-derived vasculature, reduces tumor vessel pathologies, and alleviate tumor-induced neurodegeneration. Furthermore, when combined with temozolomide, sunitinib could amplify the effects of temozolomide on glioma cells, of which the researchers thought to be related with influences of sunitinib on the brain tumor microenvironment [31].

Anti-angiogenic molecules combined with autophagy inhibitor have been proved effective in treating gliomas in vivo. Hypoxia could augment this potency possibly through stimulation of autophagosome, which is prevalent in the glioma microenvironment and late stage autophagy inhibitor may act by drive cytotoxic autophagic vacuole accumulation that is cytotoxic towards glioma cells [32].

4 Conclusion

Tumor microenvironment is a double-edged sword in occurrence, treatment and prognosis of glioma. Tumor cells can adjust its neighborhood to facilitate its own progress and microenvironment can contribute to proliferation, invasion and drug-resistance of glioma. But on the other side, targeting tumor environment may improve infiltration and efficacy of chemical agents and assist immunotherapy to take effect. All above indicate importance to further explore mechanisms related with tumor environment and make these understanding helpful to clinical treatments.

  1. Conflict of interest

    Conflict of interest statement: Authors state no conflict of interest

References

[1] Zinnhardt B, Pigeon H, Theze B, Viel T, Wachsmuth L, Fricke IB, et al. Combined PET imaging of the inflammatory tumor microenvironment identifies margins of unique radiotracer uptake. Cancer research. 201710.1158/0008-5472.CAN-16-2628Search in Google Scholar PubMed

[2] Jansen F, van Zwieten V, Coupe VM, Leemans CR, Verdonck-de Leeuw IM. A Review on Cost-Effectiveness and Cost-Utility of Psychosocial Care in Cancer Patients. Asia-Pacific journal of oncology nursing. 2016;3(2):125-13610.4103/2347-5625.182930Search in Google Scholar PubMed PubMed Central

[3] Eaton EB, Jr., Varney TR. Mesenchymal stem cell therapy for acute radiation syndrome: innovative medical approaches in military medicine. Military Medical Research. 2015;2:210.1186/s40779-014-0027-9Search in Google Scholar PubMed PubMed Central

[4] Yoshida K, Sulaiman NS, Miyawaki D, Ejima Y, Nishimura H, Ishihara T, et al. Radiotherapy for brainstem gliomas in children and adults: A single-institution experience and literature review. Asia-Pacific journal of clinical oncology. 2017;13(2):e153-e6010.1111/ajco.12451Search in Google Scholar PubMed

[5] Kanou T, Okami J, Tokunaga T, Ishida D, Kuno H, Higashiyama M. Prognostic factors in patients with postoperative brain recurrence from completely resected non-small cell lung cancer. Thoracic cancer. 2015;6(1):38-4210.1111/1759-7714.12137Search in Google Scholar PubMed PubMed Central

[6] Irvin DM, McNeill RS, Bash RE, Miller CR. Intrinsic Astrocyte Heterogeneity Influences Tumor Growth in Glioma Mouse Models. Brain pathology. 2017;27(1):36-5010.1111/bpa.12348Search in Google Scholar PubMed PubMed Central

[7] Chen W, Wang D, Du X, He Y, Chen S, Shao Q, et al. Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes. Medical oncology. 2015;32(3):4310.1007/s12032-015-0487-0Search in Google Scholar PubMed

[8] Lin Q, Liu Z, Ling F, Xu G. Astrocytes protect glioma cells from chemotherapy and upregulate survival genes via gap junctional communication. Molecular medicine reports. 2016;13(2):1329-133510.3892/mmr.2015.4680Search in Google Scholar PubMed

[9] Chen W, Xia T, Wang D, Huang B, Zhao P, Wang J, et al. Human astrocytes secrete IL-6 to promote glioma migration and invasion through upregulation of cytomembrane MMP14. Oncotarget. 2016;7(38):62425-6243810.18632/oncotarget.11515Search in Google Scholar PubMed PubMed Central

[10] Okolie O, Bago JR, Schmid RS, Irvin DM, Bash RE, Miller CR, et al. Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model. Neuro-oncology. 2016;18(12):1622-163310.1093/neuonc/now117Search in Google Scholar PubMed PubMed Central

[11] Kamran N, Kadiyala P, Saxena M, Candolfi M, Li Y, Moreno-Ayala MA, et al. Immunosuppressive Myeloid Cells’ Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. Molecular therapy: the journal of the American Society of Gene Therapy. 2017;25(1):232-24810.1016/j.ymthe.2016.10.003Search in Google Scholar PubMed PubMed Central

[12] Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, et al. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. Cancer research. 2016;76(19):5671-568210.1158/0008-5472.CAN-16-0144Search in Google Scholar PubMed PubMed Central

[13] Kundu S, Xiong A, Spyrou A, Wicher G, Marinescu VD, Edqvist PD, et al. Heparanase Promotes Glioma Progression and Is Inversely Correlated with Patient Survival. Molecular cancer research : MCR. 2016;14(12):1243-125310.1158/1541-7786.MCR-16-0223Search in Google Scholar PubMed

[14] Yao Y, Ye H, Qi Z, Mo L, Yue Q, Baral A, et al. B7-H4(B7x)- Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 2016;22(11):2778-279010.1158/1078-0432.CCR-15-0858Search in Google Scholar PubMed PubMed Central

[15] Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 2016;352(6288):aad301810.1126/science.aad3018Search in Google Scholar PubMed PubMed Central

[16] Liu Z, Han L, Dong Y, Tan Y, Li Y, Zhao M, et al. EGFRvIII/ integrin beta3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis. Oncotarget. 2016;7(4):4680-469410.18632/oncotarget.6730Search in Google Scholar PubMed PubMed Central

[17] Xia S, Lal B, Tung B, Wang S, Goodwin CR, Laterra J. Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation. Neuro-oncology. 2016;18(4):507-51710.1093/neuonc/nov171Search in Google Scholar PubMed PubMed Central

[18] Grimaldi A, D’Alessandro G, Golia MT, Grossinger EM, Di Angelantonio S, Ragozzino D, et al. KCa3.1 inhibition switches the phenotype of glioma-infiltrating microglia/macrophages. Cell death & disease. 2016;7:e217410.1038/cddis.2016.73Search in Google Scholar PubMed PubMed Central

[19] Sin WC, Aftab Q, Bechberger JF, Leung JH, Chen H, Naus CC. Astrocytes promote glioma invasion via the gap junction protein connexin43. Oncogene. 2016;35(12):1504-151610.1038/onc.2015.210Search in Google Scholar PubMed

[20] He Q, Zou X, Duan D, Liu Y, Xu Q. Malignant transformation of bone marrow stromal cells induced by the brain glioma niche in rats. Molecular and cellular biochemistry. 2016;412(1-2):1-1010.1007/s11010-015-2602-0Search in Google Scholar PubMed

[21] Gourlay J, Morokoff AP, Luwor RB, Zhu HJ, Kaye AH, Stylli SS. The emergent role of exosomes in glioma. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia. 2017;35:13-2310.1016/j.jocn.2016.09.021Search in Google Scholar PubMed

[22] Hu Q, Kang T, Feng J, Zhu Q, Jiang T, Yao J, et al. Tumor Microenvironment and Angiogenic Blood Vessels Dual-Targeting for Enhanced Anti-Glioma Therapy. ACS applied materials & interfaces. 2016;8(36):23568-2357910.1021/acsami.6b08239Search in Google Scholar PubMed

[23] An S, Lu X, Zhao W, Sun T, Zhang Y, Lu Y, et al. Amino Acid Metabolism Abnormity and Microenvironment Variation Mediated Targeting and Controlled Glioma Chemotherapy. Small. 2016;12(40):5633-564510.1002/smll.201601249Search in Google Scholar PubMed

[24] Zhao Y, Ren W, Zhong T, Zhang S, Huang D, Guo Y, et al. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity. Journal of controlled release: official journal of the Controlled Release Society. 2016;222:56-6610.1016/j.jconrel.2015.12.006Search in Google Scholar PubMed

[25] Ruan S, Yuan M, Zhang L, Hu G, Chen J, Cun X, et al. Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles. Biomaterials. 2015;37:425-43510.1016/j.biomaterials.2014.10.007Search in Google Scholar PubMed

[26] Zhang B, Shen S, Liao Z, Shi W, Wang Y, Zhao J, et al. Targeting fibronectins of glioma extracellular matrix by CLT1 peptide-conjugated nanoparticles. Biomaterials. 2014;35(13):4088-409810.1016/j.biomaterials.2014.01.046Search in Google Scholar PubMed

[27] 27. Cockle JV, Rajani K, Zaidi S, Kottke T, Thompson J, Diaz RM, et al. Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro-oncology. 2016;18(4):518-52710.1093/neuonc/nov173Search in Google Scholar PubMed PubMed Central

[28] Qiao J, Dey M, Chang AL, Kim JW, Miska J, Ling A, et al. Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy. Oncoimmunology. 2015;4(8):e102230210.1080/2162402X.2015.1022302Search in Google Scholar PubMed PubMed Central

[29] Zhang Y, Luo F, Li A, Qian J, Yao Z, Feng X, et al. Systemic injection of TLR1/2 agonist improves adoptive antigen-specific T cell therapy in glioma-bearing mice. Clinical immunology. 2014;154(1):26-3610.1016/j.clim.2014.06.004Search in Google Scholar PubMed

[30] Renner DN, Malo CS, Jin F, Parney IF, Pavelko KD, Johnson AJ. Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2016;13(1):226-23610.1007/s13311-015-0407-1Search in Google Scholar PubMed PubMed Central

[31] Hatipoglu G, Hock SW, Weiss R, Fan Z, Sehm T, Ghoochani A, et al. Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment. Cancer science. 2015;106(2):160-17010.1111/cas.12580Search in Google Scholar PubMed PubMed Central

[32] Lobo MR, Wang X, Gillespie GY, Woltjer RL, Pike MM. Combined efficacy of cediranib and quinacrine in glioma is enhanced by hypoxia and causally linked to autophagic vacuole accumulation. PloS one. 2014;9(12):e11411010.1371/journal.pone.0114110Search in Google Scholar PubMed PubMed Central

Received: 2017-3-26
Accepted: 2017-4-15
Published Online: 2017-8-12

© 2017 Guijie Li et al.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Articles in the same Issue

  1. Regular Articles
  2. Intravascular treatment of left subclavian artery aneurysm coexisting with aortic coarctation in an adult patient
  3. Regular Articles
  4. Effect of electrical stimulation on blood flow velocity and vessel size
  5. Regular Articles
  6. Live birth pregnancy outcome after first in vitro fertilization treatment in a patient with Systemic Lupus Erythematosus and isolated high positive IgA anti-β2glycoprotein I antibodies: a case report
  7. Regular Articles
  8. Periodontal ligament stem cells regulate apoptosis of neutrophils
  9. Regular Articles
  10. Platelet-rich fibrin (PRF) in implants dentistry in combination with new bone regenerative flapless technique: evolution of the technique and final results
  11. Regular Articles
  12. The significance of strong ion gap for predicting return of spontaneous circulation in patients with cardiopulmonary arrest
  13. Regular Articles
  14. Clinicopathology of EpCAM and EGFR in human epithelial ovarian carcinoma
  15. Regular Articles
  16. Intraosseous lipoma of the mandibula: A case report and review of the literature
  17. Regular Articles
  18. Transurethral resection of the prostate, bladder explosion and hyponatremic encephalopathy: a rare case report of malpractice
  19. Regular Articles
  20. Brain strokes related to aortic aneurysma – the analysis of three cases
  21. Regular Articles
  22. Effect of Bicyclol tablets on drug induced liver injuries after kidney transplantation
  23. Regular Articles
  24. Plasma free fatty acids in hyperemesis gravidarum pregnancy
  25. Regular Articles
  26. Impact of chromosomal rearrangement upon DNA methylation patterns in leukemia
  27. Regular Articles
  28. Gefitinib versus docetaxel in treated non-small-cell lung cancer: a meta-analysis
  29. Regular Articles
  30. The clinical characteristics of patients with chronic idiopathic anal pain
  31. Regular Articles
  32. Bone tunnel impaction reduced the tibial tunnel enlargement
  33. Regular Articles
  34. Effects of S-1 combined with radiotherapy in the treatment of nasopharyngeal cancer: a meta-analysis based on randomized controlled trials
  35. Regular Articles
  36. Predictions and outcomes of atrial fibrillation in the patients with acute myocardial infarction
  37. Regular Articles
  38. An accuracy study of the Intracavitary Electrocardiogram (IC-ECG) guided peripherally inserted central catheter tip placement among neonates
  39. Regular Articles
  40. Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: A meta-analysis
  41. Regular Articles
  42. Surface coil intensity correction in magnetic resonance imaging in spinal metastases
  43. Regular Articles
  44. Muscle stem cell and physical activity: what point is the debate at?
  45. Regular Articles
  46. MicroRNA let-7g directly targets forkhead box C2 (FOXC2) to modulate bone metastasis in breast cancer
  47. Regular Articles
  48. Monitoring health inequalities at the municipal level: Lithuanian experience
  49. Regular Articles
  50. Role of Epstein-Barr virus in the development of nasopharyngeal carcinoma
  51. Regular Articles
  52. Thrombectomy combined with indwelling-catheter thrombolysis is more effective than pure thrombectomy for the treatment of lower extremity deep venous thrombosis
  53. Regular Articles
  54. Expression of Hepcidin and Neogenin in colorectal cancer
  55. Regular Articles
  56. Carnitine and adiponectin levels in breast cancer after radiotherapy
  57. Regular Articles
  58. Pathophysiology of meningioma growth in pregnancy
  59. Regular Articles
  60. Causal neuro-immune relationships at patients with chronic pyelonephritis and cholecystitis. Correlations between parameters EEG, HRV and white blood cell count
  61. Regular Articles
  62. Measuring efficiency of secondary healthcare providers in Slovenia
  63. Regular Articles
  64. Galectin-3 expression in colorectal cancer and its correlation with clinical pathological characteristics and prognosis
  65. Regular Articles
  66. Model for studying anti- allergic drugs for allergic conjunctivitis in animals
  67. Regular Articles
  68. Barriers perceived by nurses in the optimal treatment of postoperative pain
  69. Regular Articles
  70. Tumor microenvironment in treatment of glioma
  71. Regular Articles
  72. Delirium risk of dexmedetomidine and midazolam in patients treated with postoperative mechanical ventilation: A meta-analysis
  73. Regular Articles
  74. Hemangioma of the rib: a rare case report and literature review
  75. Regular Articles
  76. The diagnostic accuracy of conventional forceps biopsy compared to ESD
  77. Regular Articles
  78. Increased miR-25 expression in serum of gastric cancer patients is correlated with CA19-9 and acts as a potential diagnostic biomarker
  79. Regular Articles
  80. Therapeutic nanomedicine surmounts the limitations of pharmacotherapy
  81. Regular Articles
  82. Relationship between PD-L1 expression and clinical characteristics in patients with breast invasive ductal carcinoma
  83. Regular Articles
  84. Trypsinogen activation peptide induces HMGB1 release from rat pancreatic acinar cells
  85. Regular Articles
  86. The effective regulation of pro- and anti-inflammatory cytokines induced by combination of PA-MSHA and BPIFB1 in initiation of innate immune responses
  87. Regular Articles
  88. Cell based therapeutic approach in vascular surgery: application and review
  89. Regular Articles
  90. Clinical efficacy of alprostadil combined with α-lipoic acid in the treatment of elderly patients with diabetic nephropathy
  91. Regular Articles
  92. Professional burnout and concurrent health complaints in neonatal nursing
  93. Regular Articles
  94. Esophageal xanthoma: presence of M2 macrophages suggests association with late inflammatory and reparative processes
  95. Regular Articles
  96. Cone beam computed tomography analysis in 3D position of maxillary denture
  97. Regular Articles
  98. CK20 mRNA expression in serum as a biomarker for colorectal cancer diagnosis: A meta-analysis
  99. Regular Articles
  100. Serum AFU, 5’-NT and AFP as biomarkers for primary hepatocellular carcinoma diagnosis
  101. Regular Articles
  102. Absolute reliability and concurrent validity of hand held dynamometry and isokinetic dynamometry in the hip, knee and ankle joint: systematic review and meta-analysis
  103. Regular Articles
  104. The Fountain of Youth: A tale of parabiosis, stem cells, and rejuvenation
  105. Regular Articles
  106. Foam sclerotherapy during shunt surgery for portal hypertension and varices
  107. Regular Articles
  108. Insomnia and depression: Japanese hospital workers questionnaire survey
  109. Regular Articles
  110. Serum NF-κBp65, TLR4 as biomarker for diagnosis of preeclampsia
  111. Regular Articles
  112. Docetaxel/cisplatin therapy in myasthenia gravis with hypertension/diabetes
  113. Regular Articles
  114. Fluid resuscitation and markers of glycocalyx degradation in severe sepsis
  115. Regular Articles
  116. Modified Sauve-Kapandji procedure for patients with old fractures of the distal radius
  117. Regular Articles
  118. Bile leakage after liver transplantation
  119. Regular Articles
  120. VEGF overexpression predicts poor survival in hepatocellular carcinoma
  121. Regular Articles
  122. Galen vein aneurysm– challenge for treatment
  123. Regular Articles
  124. Retrieval of a broken sewing needle from the sacrum aided by a permanent magnet: a case report and literature review
  125. Regular Articles
  126. HIV/STI prevention interventions: A systematic review and meta-analysis
  127. Regular Articles
  128. Aortic aneurysm as a complication of myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis
  129. Regular Articles
  130. Real-time monitoring of contrast-enhanced ultrasound for radio frequency ablation
  131. Regular Articles
  132. Successful drug-eluting stent implantation in a male patient with dextrocardia: a case report
  133. Regular Articles
  134. Primary pleomorphic liposarcoma of fallopian tube with recurrence: a case report and review of the literature
  135. Regular Articles
  136. Color Doppler Ultrasound in Uterine Arterial Embolization
  137. Regular Articles
  138. Pattern of alcohol consumption by young people from North Eastern Portugal
  139. Regular Articles
  140. Effects of out-of-hospital continuing nursing on schizophrenia patients' rehabilitation and quality of life
Downloaded on 25.1.2026 from https://www.degruyterbrill.com/document/doi/10.1515/med-2017-0035/html
Scroll to top button